The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.

Oncotarget · 2015 · PMC4673195 · PMID 26068951

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally significantp = 0.06so close (0.05 < p ≤ 0.1)

Surprisingly, sudemycin D1 induced a moderate increase of pBtk levels both in SF3B1 -mutated and unmutated CLL cases ( p = 0.06, marginally significant).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.